BIO Comments on FDA Draft Guidance on Grandfathering Policy for Packages and Homogenous Cases of Product Without Product Identifier
January 26, 2018
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier.
BIO and its member companies are committed to meeting the requirements of the Drug Supply Chain Security Act (DSCSA) and ensuring the U.S. drug supply chain is secure, patients are receiving authentic products, and legitimate medications continue to move without unnecessary delays.
The use of the package date for determining whether an un-serialized product would be grandfathered is critical to a smooth transition under DSCSA from un-serialized to serialized inventory. It’s important these products can be sold and distributed until the product has reached its expiration date.
BIO thanks the FDA for listening to stakeholder concerns on the implementation of the grandfathering provisions of the DSCSA. This draft guidance will help ensure legitimate product can move through the supply chain and help negate potential issues as stakeholders begin implementing the serialization requirements.
Download Full Comments Below
2018-01-26 BIO Comments On DSCSA Grandfathering Policy FINAL
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier.
BIO and its member companies are committed to meeting the requirements of the Drug Supply Chain Security Act (DSCSA) and ensuring the U.S. drug supply chain is secure, patients are receiving authentic products, and legitimate medications continue to move without unnecessary delays.
The use of the package date for determining whether an un-serialized product would be grandfathered is critical to a smooth transition under DSCSA from un-serialized to serialized inventory. It’s important these products can be sold and distributed until the product has reached its expiration date.
BIO thanks the FDA for listening to stakeholder concerns on the implementation of the grandfathering provisions of the DSCSA. This draft guidance will help ensure legitimate product can move through the supply chain and help negate potential issues as stakeholders begin implementing the serialization requirements.